Safety and Efficacy of the OmniaSecure Defibrillation Lead: Final Results From LEADR

Authors, Journal, Affiliations, Type, DOI

Overview

LEADR is the pivotal trial of the 4.7-F lumenless, single-coil, integrated bipolar OmniaSecure defibrillation lead implanted in standard right ventricular positions. At a mean follow-up of 32.4 months, 643 of 657 patients (97.9%) were successfully implanted; freedom from lead-related major complications was 96.5% at 3 years, appropriate therapy was delivered to 22.3% of patients, antitachycardia pacing efficacy was 75.4%, and inappropriate shocks occurred in 2.7% at 1 year and 5.9% at 3 years. Electrical parameters remained stable, with one lead fracture at 2.3 years. The trial establishes the medium-term durability of the lead platform in the right ventricle but did not test conduction-system placement, which is the subject of the separate LEADR LBBAP trial (sources/leadr-lbbap-primary-hrs-2026; sources/leadr-lbbap-hrs-2025).

Keywords

Cardiac resynchronization therapy; Catheters; Defibrillator; Freedom; Hospitalization

Key Takeaways

Study design and population

Lead description and design

Defibrillation efficacy

Ambulatory efficacy

Inappropriate therapy

Safety and reliability

Electrical and sensing performance

Interpretation

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated